Nitrendipino [Inn-Spanish]
Brand names,
Nitrendipino [Inn-Spanish]
Analogs
Nitrendipino [Inn-Spanish]
Brand Names Mixture
Nitrendipino [Inn-Spanish]
Chemical_Formula
C18H20N2O6
Nitrendipino [Inn-Spanish]
RX_link
No information avaliable
Nitrendipino [Inn-Spanish]
fda sheet
Nitrendipino [Inn-Spanish]
msds (material safety sheet)
Nitrendipino [Inn-Spanish]
Synthesis Reference
H. Meyar et al., Ger. pat 2117571; eidem, US pat. 3799934
Nitrendipino [Inn-Spanish]
Molecular Weight
360.361 g/mol
Nitrendipino [Inn-Spanish]
Melting Point
156-160 oC
Nitrendipino [Inn-Spanish]
H2O Solubility
Insoluble
Nitrendipino [Inn-Spanish]
State
Solid
Nitrendipino [Inn-Spanish]
LogP
2.756
Nitrendipino [Inn-Spanish]
Dosage Forms
No information avaliable
Nitrendipino [Inn-Spanish]
Indication
For the treatment of mild to moderate hypertension
Nitrendipino [Inn-Spanish]
Pharmacology
Nitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Nitrendipino [Inn-Spanish]
Absorption
No information avaliable
Nitrendipino [Inn-Spanish]
side effects and Toxicity
No information avaliable
Nitrendipino [Inn-Spanish]
Patient Information
No information avaliable
Nitrendipino [Inn-Spanish]
Organisms Affected
Humans and other mammals